CA2770403C - Intravenous formulations of neurokinin-1 antagonists - Google Patents

Intravenous formulations of neurokinin-1 antagonists Download PDF

Info

Publication number
CA2770403C
CA2770403C CA2770403A CA2770403A CA2770403C CA 2770403 C CA2770403 C CA 2770403C CA 2770403 A CA2770403 A CA 2770403A CA 2770403 A CA2770403 A CA 2770403A CA 2770403 C CA2770403 C CA 2770403C
Authority
CA
Canada
Prior art keywords
compound
composition
pharmaceutical composition
triglyceride
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2770403A
Other languages
English (en)
French (fr)
Other versions
CA2770403A1 (en
Inventor
Jiansheng Wan
Pranav Gupta
David Monteith
Soumendu Bhattacharya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opko Health Inc
Original Assignee
Opko Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Health Inc filed Critical Opko Health Inc
Publication of CA2770403A1 publication Critical patent/CA2770403A1/en
Application granted granted Critical
Publication of CA2770403C publication Critical patent/CA2770403C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2770403A 2009-08-14 2010-08-12 Intravenous formulations of neurokinin-1 antagonists Active CA2770403C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23412909P 2009-08-14 2009-08-14
US61/234,129 2009-08-14
PCT/US2010/045317 WO2011019911A1 (en) 2009-08-14 2010-08-12 Intravenous formulations of neurokinin-1 antagonists

Publications (2)

Publication Number Publication Date
CA2770403A1 CA2770403A1 (en) 2011-02-17
CA2770403C true CA2770403C (en) 2020-09-01

Family

ID=43586486

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2770403A Active CA2770403C (en) 2009-08-14 2010-08-12 Intravenous formulations of neurokinin-1 antagonists

Country Status (15)

Country Link
US (2) US9101615B2 (https=)
EP (2) EP3143996A1 (https=)
JP (2) JP5860399B2 (https=)
KR (1) KR101834577B1 (https=)
CN (2) CN102573475B (https=)
AU (1) AU2010282483B2 (https=)
BR (1) BR112012003263A2 (https=)
CA (1) CA2770403C (https=)
ES (1) ES2609640T3 (https=)
IL (1) IL217942A0 (https=)
MX (1) MX336071B (https=)
RU (2) RU2017145628A (https=)
SG (2) SG10201407538WA (https=)
TW (2) TW201604195A (https=)
WO (1) WO2011019911A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2662374A1 (en) * 2006-04-05 2013-11-13 OPKO Health, Inc. Salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl]-8-phenyl-1,7 -diaza-spiro[4.5]decan-2-one and preparation process therefor
SG10201500028RA (en) 2006-04-05 2015-02-27 Opko Health Inc Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
AR066191A1 (es) 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
KR101719004B1 (ko) 2008-09-05 2017-03-22 옵코 헬스, 인크. 8-［｛1-（3,5-비스-（트리플루오로메틸）페닐）-에톡시｝-메틸］-8-페닐-1,7-디아자-스피로［4.5］데칸-2-온 화합물의 합성 방법 및 중간체
CN102573475B (zh) 2009-08-14 2016-01-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
AR097683A1 (es) * 2013-09-26 2016-04-06 Lilly Co Eli Compuestos y uso para la preparación de agentes de formación de imagen tau y formulaciones para la formación de imagen tau
WO2016044784A1 (en) 2014-09-19 2016-03-24 Heron Therapeutics, Inc. Emulson formulations of aprepitant
CA2978736C (en) 2015-03-04 2023-11-07 Vanda Pharmaceuticals Inc. Dosing regimen of tradipitant
US20180250270A1 (en) 2015-09-11 2018-09-06 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
US9974742B2 (en) * 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
KR20180118136A (ko) * 2016-02-01 2018-10-30 헤론 테라퓨틱스 인코포레이티드 Nk-1 수용체 길항제를 포함하는 에멀젼
US20190175702A1 (en) * 2016-08-03 2019-06-13 Zhuhai Beihai Biotech Co., Ltd. Formulations of fosaprepitant and aprepitant
US20190307734A1 (en) * 2016-11-21 2019-10-10 Zhuhai Beihai Biotech Co., Ltd. Formulations of rolapitant
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
WO2019005830A1 (en) * 2017-06-26 2019-01-03 Fordoz Pharma Corp. NANOSOME FORMULATIONS OF APREPITANT AND METHODS AND APPLICATIONS THEREOF
CN121221782A (zh) 2017-06-30 2025-12-30 傲拓神经科学公司 用于治疗抑郁的nk-1拮抗剂组合物和方法
CN109200018A (zh) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 含有奈妥吡坦的微乳制剂
CN108703950B (zh) * 2018-08-27 2021-04-20 辅必成（上海）医药科技有限公司 一种罗拉吡坦的乳剂注射液
CN109453115A (zh) * 2018-12-25 2019-03-12 广州白云山汉方现代药业有限公司 一种罗拉匹坦静脉注射乳剂及其制备方法和应用
CN109394693A (zh) * 2018-12-25 2019-03-01 广州白云山汉方现代药业有限公司 一种罗拉匹坦乳剂及其制备方法和应用
EP3991730A4 (en) 2019-06-28 2023-08-09 Shanghai Shengdi Pharmaceutical Co., Ltd NEUROKININ-1 ANTAGONIST
AU2021246889A1 (en) 2020-04-03 2022-10-13 Nerre Therapeutics Limited An NK-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ARDS) or multiple organ dysfunction syndrome (MODS)
CA3177477A1 (en) 2020-06-02 2021-12-09 Nerre Therapeutics Limited Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs
AU2021407138A1 (en) * 2020-12-25 2023-06-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Use of nk1 antagonist prodrug compound in combination with 5-ht3 receptor antagonist
EP4464712A4 (en) * 2022-01-12 2025-07-23 Jiangsu Hengrui Pharmaceuticals Co Ltd CRYSTALLINE FORM OF A NEUROKININ-1 ANTAGONIST PRODRUG COMPOUND
CA3247908A1 (en) * 2022-01-12 2025-07-10 Jiangsu Hengrui Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITION COMPRISING A NEUROKIN-1 ANTAGONIST PROMEDICINE COMPOUND
CN119528985A (zh) 2023-08-28 2025-02-28 科睿迪(南京)医药科技有限公司 神经激肽-1受体拮抗剂化合物

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0338372A3 (en) * 1988-04-22 1991-10-09 American Cyanamid Company Solubilized pro-drugs
HUT60139A (en) * 1989-07-07 1992-08-28 Endorecherche Inc Process for producing pharmaceutical composition suitable for treating prostate cancer connected with androgen
US5610140A (en) * 1991-04-01 1997-03-11 Cortech, Inc. Bradykinin receptor antagonists with neurokinin receptor blocking activity
AU678409B2 (en) 1992-10-28 1997-05-29 Merck Sharp & Dohme Limited 4-arylmethyloxymethyl piperidines as tachykinin antagonists
US5661162A (en) 1992-12-14 1997-08-26 Merck Sharp & Dohme Limited 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperdines as tachykinin receptor antagonists
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
ATE170174T1 (de) 1994-01-13 1998-09-15 Merck Sharp & Dohme Gem-bissubstituierte azazyclische tachykinin- antagonisten
WO1996026726A1 (en) 1995-02-28 1996-09-06 Hoechst Marion Roussel, Inc. Pharmaceutical composition for piperidinoalkanol compounds
SE9503143D0 (sv) * 1995-09-12 1995-09-12 Astra Ab New preparation
GB9601680D0 (en) 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
ATE265209T1 (de) 1996-07-17 2004-05-15 Merck & Co Inc Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten
CA2287397A1 (en) 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Use of an nk-1 receptor antagonist and an ssri for treating obesity
JP3571511B2 (ja) * 1997-11-11 2004-09-29 トーアエイヨー株式会社 経皮吸収製剤
US6380242B1 (en) 1998-12-23 2002-04-30 Nps Allelix Corp. N-alkylamino-indoles for the treatment of migraine
MXPA01011981A (es) 1999-05-24 2003-09-04 Sonus Pharma Inc Vehiculo de emulsion para farmacos poco solubles.
US6436928B1 (en) 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
ES2258485T3 (es) 1999-12-17 2006-09-01 Schering Corporation Antagonistas selectivos de neuroquinina.
US6499984B1 (en) 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
MY128450A (en) * 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
JP2004526706A (ja) 2001-02-12 2004-09-02 テバ ファーマシューティカル インダストリーズ リミティド オクスカルバゼピンの新しい結晶形態及びそれらの調製方法
ATE374183T1 (de) 2001-11-13 2007-10-15 Schering Corp Nk1-antagonisten
PE20030762A1 (es) * 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
AU2003277299B2 (en) * 2002-04-10 2009-12-10 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
ATE358482T1 (de) 2002-07-03 2007-04-15 Schering Corp 1-amido-4-phenyl-4-benzyloxymethyl-piperidin derivative und verwandte verbindungen als neurokinin-1 (nk-1) antagonsisten zur behandlung von erbrechen, depressionen, angstzustände und husten
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7323459B2 (en) 2002-12-24 2008-01-29 Teva Pharmaceutical Industries Ltd. Crystal forms, methods for their preparation and method for preparation of olanzapine
GB0321256D0 (en) 2003-09-11 2003-10-08 Generics Uk Ltd Novel crystalline compounds
EP1682545B1 (en) 2003-10-03 2007-12-12 Pfizer Limited Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
AU2004308935A1 (en) * 2003-12-22 2005-07-14 Schering Corporation Pharmaceutical compositions
JP2008505107A (ja) 2004-07-01 2008-02-21 シェーリング　コーポレイション Ｎｋ１アンタゴニストとしてのピペリジン誘導体
US7871632B2 (en) * 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
WO2006060580A1 (en) * 2004-11-30 2006-06-08 Myriad Genetics, Inc. Therapeutic formulations
CN100367951C (zh) 2005-12-16 2008-02-13 石药集团恩必普药业有限公司 丁苯酞静脉乳剂及其应用
PE20071019A1 (es) * 2006-03-06 2007-10-29 Wyeth Corp Formulaciones farmaceuticas liquidas y semi-solidas que comprenden un modulador de receptores estrogenicos
EP2662374A1 (en) 2006-04-05 2013-11-13 OPKO Health, Inc. Salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl]-8-phenyl-1,7 -diaza-spiro[4.5]decan-2-one and preparation process therefor
SG10201500028RA (en) 2006-04-05 2015-02-27 Opko Health Inc Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
CN101110758A (zh) 2006-07-21 2008-01-23 华为技术有限公司 建立紧急会话的方法、系统及代理呼叫会话控制功能
MX2009001208A (es) 2006-08-07 2009-04-14 Stiefel Laboratories Compuestos cristalinos antifungicos.
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
AR066191A1 (es) 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
KR101719004B1 (ko) 2008-09-05 2017-03-22 옵코 헬스, 인크. 8-［｛1-（3,5-비스-（트리플루오로메틸）페닐）-에톡시｝-메틸］-8-페닐-1,7-디아자-스피로［4.5］데칸-2-온 화합물의 합성 방법 및 중간체
CN102573475B (zh) 2009-08-14 2016-01-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂

Also Published As

Publication number Publication date
EP2464230B1 (en) 2016-10-05
US20160024092A1 (en) 2016-01-28
MX2012001872A (es) 2012-04-11
US9101615B2 (en) 2015-08-11
RU2642234C2 (ru) 2018-01-24
JP2013501806A (ja) 2013-01-17
JP2016041734A (ja) 2016-03-31
EP3143996A1 (en) 2017-03-22
JP6308991B2 (ja) 2018-04-11
AU2010282483B2 (en) 2014-09-04
CN102573475B (zh) 2016-01-20
TWI498329B (zh) 2015-09-01
KR20120060215A (ko) 2012-06-11
EP2464230A1 (en) 2012-06-20
MX336071B (es) 2016-01-06
EP2464230A4 (en) 2013-01-02
TW201111382A (en) 2011-04-01
TW201604195A (zh) 2016-02-01
WO2011019911A1 (en) 2011-02-17
SG10201407538WA (en) 2015-01-29
US20110038925A1 (en) 2011-02-17
CN105503870A (zh) 2016-04-20
RU2012109405A (ru) 2013-09-20
ES2609640T3 (es) 2017-04-21
BR112012003263A2 (pt) 2015-09-22
JP5860399B2 (ja) 2016-02-16
AU2010282483A1 (en) 2012-03-01
CN102573475A (zh) 2012-07-11
IL217942A0 (en) 2012-03-29
CA2770403A1 (en) 2011-02-17
SG178403A1 (en) 2012-03-29
KR101834577B1 (ko) 2018-03-05
RU2017145628A (ru) 2019-02-19

Similar Documents

Publication Publication Date Title
CA2770403C (en) Intravenous formulations of neurokinin-1 antagonists
US9339553B2 (en) Liquid compositions of insoluble drugs and preparation methods thereof
US9974742B2 (en) Emulsion formulations of an NK-1 receptor antagonist and uses thereof
JP4643641B2 (ja) 高水溶性薬物を送達するための組成物
BR112012027279B1 (pt) composições de emulsão farmacêutica com baixo teor de óleo que compreendem progestogênio
KR101722398B1 (ko) ｐＨ 조절제를 포함하는 탁산의 약학적 용액 및 이의 제조 방법
JP6552967B2 (ja) 経口および非経口送達用のクロピドグレル遊離塩基の安定な医薬組成物
CA3123002A1 (en) Stable formulations of anesthetics and associated dosage forms
US20220347096A1 (en) Liposomal cannabinoids and uses thereof
US20190231688A1 (en) Method of administering emulsion formulations of an nk-1 receptor antagonist
AU2014271269B2 (en) Intravenous formulations of neurokinin-1 antagonists
HK1172244B (en) Intravenous formulations of rolapitant
US20180185280A1 (en) Propofol emulsion for parenteral administration
HK1100062B (en) Compositions for delivering highly water soluble drugs

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150707

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240802

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240802

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250808

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250808